Literature DB >> 1600314

Cushing's syndrome due to primary pigmented nodular adrenocortical disease with cardiac myxomas and mucocutaneous lentigines.

Y Ichiba1, Y Nishizaki, M Tanizaki.   

Abstract

A young Japanese female demonstrated unusual features of Cushing's syndrome, cardiac myxomas and mucocutaneous lentigines. At the age of 12 years she presented with growth failure and obesity. The dexamethasone suppression test, the metyrapone test and low corticotropin concentrations indicated a primary adrenal disorder. At surgery, the adrenal glands were not enlarged (the right, 4.0 g; the left; 4.5 g) but had numerous small dark brown nodules. The pathological findings showed multiple small black cortical nodules containing large cells with eosinophilic cytoplasm and lipofuscin, and internodular cortical atrophy. These abnormalities were consistent with primary pigmented nodular adrenocortical disease. At age 22 years she complained of fatigue and palpitations associated with mid-chest pain. Four cardiac myxomas, suspected from the echocardiogram, were surgically removed. Because Cushing's syndrome and cardiac myxomas are life-threatening conditions, an awareness of the complex is important.

Entities:  

Mesh:

Year:  1992        PMID: 1600314     DOI: 10.1111/j.1651-2227.1992.tb12089.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  2 in total

1.  The variations in the immunologic features and interleukin-6 levels for the surgical treatment of cardiac myxomas.

Authors:  Hiroki Yokomuro; Katsunori Yoshihara; Yoshinori Watanabe; Noritsugu Shiono; Nobuya Koyama; Yoshinori Takanashi
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

2.  Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2.

Authors:  C A Stratakis; J A Carney; J P Lin; D A Papanicolaou; M Karl; D L Kastner; E Pras; G P Chrousos
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.